Google DeepMind CEO Demis Hassabis Announces AI-Driven Cancer Drug Trials to Begin in Early 2026, Robotics Breakthroughs Expected

Demis Hassabis, CEO of Google DeepMind, revealed that Isomorphic Labs—the company's AI-driven drug discovery spinout—is rapidly advancing toward clinical reality. With 17 active projects across multiple disease areas, the first anticancer drug candidate is expected to enter human trials in early 2026. Isomorphic Labs leverages DeepMind's AlphaFold protein-folding technology and other deep learning models to design novel molecules with high specificity, potentially slashing the typical decade-long drug development timeline. Hassabis emphasized that AI can explore vastly larger chemical spaces than traditional methods, identifying promising compounds that might otherwise be overlooked.

In addition to the drug pipeline, Hassabis predicted significant robotics breakthroughs within the next 18 months, hinting at tighter integration between DeepMind's reinforcement learning research and physical robotic systems. This aligns with ongoing work on general-purpose manipulation and autonomous task execution. For professionals, these developments signal a paradigm shift: AI-driven drug discovery is moving from research labs to clinical validation, while physical AI could soon transform logistics, manufacturing, and healthcare automation. The combination of biotech and robotics advances underscores DeepMind's broader mission to solve intelligence and then use it to solve everything else.